<p>Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation</p>-Reference-Cited by-同舟云学术

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation

Published:2020-03 Issue: Volume:Volume 11 Page:77-81
ISSN:1179-2736
Container-title:Journal of Blood Medicine
language:en
Short-container-title:JBM

Author:

Russo Vincenzo,Paccone Andrea,Rago Anna,Maddaloni Valeria,Iafusco Dario,Proietti Riccardo,Atripaldi Umberto,D'Onofrio Antonio,Golino Paolo,Nigro Gerardo^ORCID

Publisher

Informa UK Limited

Subject

Hematology

Reference27 articles.

1. Excess Body Weight and Incidence of Stroke

2. A Novel Pathway to the Manifestations of Metabolic Syndrome

3. Glomerular hemodynamics in severe obesity

4. Comparison of initial warfarin response in obese patients versus non-obese patients

5. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and cardiovascular disease: risk assessment, physical activity, and management of complications;International Journal of Cardiology Cardiovascular Risk and Prevention;2024-09

2. Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials;Biomedicines;2023-01-04

3. Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?;Journal of Clinical Medicine;2022-10-28

4. Pharmacokinetic determinants for the right dose of antiarrhythmic drugs;Expert Opinion on Drug Metabolism & Toxicology;2022-03-02

5. Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study;Journal of Blood Medicine;2021-06